regdanvimab
Sign in to saveRegdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Spike protein of SARS-CoV-2
- Drug.tradename
- Regkirona
- Drug.licence_EU
- yes
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J06
- Drug.ATC_suffix
- BD06
- Drug.legal_AU
- S4
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 2444308-95-4
- Drug.DrugBank
- DB16405
- Drug.UNII
- I0BGE6P6I6
- Drug.KEGG
- D12241
- Drug.synonyms
- CT-P59
via Wikipedia infobox
~2 min read
Article
7 sectionsContents
- Medical uses
- Society and culture
- Legal status
- Names
- References
- Further reading
- External links
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.
The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis.
Connections
monoclonal antibody
Entity
casirivimab/imdevimab
Entity
AZD7442
Medication
SARS-CoV-2
Entity
bamlanivimab/etesevimab
Entity
human
Entity
COVID-19
Entity
fungi
Entity
virus
Entity
bacteria
Entity
digital object identifier
Entity
infection
Entity
Q180686
Entity
antigen
Entity
toxin
Entity
CAS Registry Number
Entity
Q229883
Entity
Anatomical Therapeutic Chemical Classification System
Entity
intravenous infusion and defusion
Entity
clinical trial
Entity